# US 2026/0092035 A1 · Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092035 A1
- Document ID: US20260092035A1
- Status: Published application
- Kind: A1
- Application number: 19/413,522
- Filed: 2025-12-09
- Published: 2026-04-02
- Earliest claimed: 2023-11-14
- Assignees: Mindset Pharma Inc.
- Applicants: Mindset Pharma Inc.
- Inventors: Abdelmalik SLASSI
- Web page: https://patentgrep.com/patent/US20260092035A1

## CPC

- A61P 25/00: Drugs for disorders of the nervous system
- C07D 209/16: Tryptamines
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- C07B 59/002: {Heterocyclic compounds}
- C07D 209/44: Iso-indoles; Hydrogenated iso-indoles
- C07D 209/46: with an oxygen atom in position 1
- C07D 209/48: with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/14: containing three or more hetero rings
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 409/14: containing three or more hetero rings
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present disclosure relates to indole derivatives of general Formula (I), to processes for their preparation, to compositions including them and to their use in activation of a serotonin receptors in a cell, as well as to treating diseases, disorders, or conditions by activation of a serotonin receptors in a cell. The diseases, disorders, or conditions include, for example, psychosis, mental illnesses, and central nervous system (CNS) disorders.

## Claims

### Claim 1

A compound of Formula (I)
or a pharmaceutically acceptable salt, solvate, and/or prodrug thereof,
wherein:
X is O;
R1 is H;
R2 is selected from H, halo, and C1-C6alkyl;
R3 is H;
R4 is selected from H, CN, halo, C1-C6alkyl, C2-C6alkenyl, and C2-C6alkynyl;
R5 is selected from H, CN, halo, C1-C6alkyl, C2-C6alkenyl, and C2-C6alkynyl;
R6 is selected from H, C1-C10alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkenyleneZR14, C2-C6alkenyleneZR14, C2-C6alkynyleneZR14, C3-C7cycloalkyl, C3-C10heterocycloalkyl, C1-C6alkenyleneC3-C7cycloalkyl, C1-C6alkenyleneC3-C10heterocycloalkyl, and C1-C6alkenyleneC5-C10heteroaryl, the latter five groups being optionally substituted with one to four substituents independently selected from halo, C1-C6alkyl, OR15, and C(O)R15;
R7 is selected from H, halo, and C1-C6alkyl;
R8 is selected from H, halo, and C1-C6alkyl;
R9 is selected from H and halo;
R10 is selected from H and halo;
R11 is selected from H, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkenyleneZ′R16, C2-C6alkenyleneZ′R16, C2-C6alkynyleneZ′R16, C3-C7cycloalkyl, C3-C10heterocycloalkyl, C6-C10aryl, C5-C10heteroaryl, C1-C6alkyleneC3-C7cycloalkyl, C1-C6alkenyleneC3-C10heterocycloalkyl, C1-C6alkyleneC6-C10aryl, and C1-C6alkyleneC5-C10heteroaryl, the latter eight groups being optionally substituted with one to four substituents independently selected from halo, C1-C6alkyl, OR17, and C(O)R17;
R12 is selected from C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkenyleneZ′R16, C2-C6alkenyleneZ′R16, C2-C6alkynyleneZ′R16, C3-C7cycloalkyl, C3-C10heterocycloalkyl, C6-C10aryl, C5-C10heteroaryl, C1-C6alkenyleneC3-C7cycloalkyl, C1-C6alkenyleneC3-C10heterocycloalkyl, C1-C6alkyleneC6-C10aryl, and C1-C6alkyleneC5-C10heteroaryl, the latter eight groups being optionally substituted with one to four substituents independently selected from halo, C1-C6alkyl, OR17, and C(O)R17; or
R11 and R12 are taken together with the nitrogen atom therebetween to form a monocyclic 3- to 7-membered heterocyclic ring optionally comprising 1 to 3 additional ring heteromoieties selected from O, S, S(O), SO2, N, and NR18 and/or optionally comprising one or two C═O groups, wherein said monocyclic 3- to 7-membered heterocyclic ring is further optionally substituted with one to four substituents independently selected from halo, C1-C6alkyl, OH, OC1-C6alkyl, C1-C6alkenyleneOH, and C1-C6alkenyleneOC1-C6alkyl;
Z is selected from O, C(O), NR19C(O), NR18C(O)O, OC(O)NR19, and NR19;
each Z′ is independently selected from O, C(O), NR20C(O), NR20C(O)O, C(O)NR20, OC(O)NR20, and NR20;
R14 is selected from H, C1-C6alkyl, C3-C7cycloalkyl, C3-C10heterocycloalkyl, C6-C10aryl, and C5-C10heteroaryl, the latter four groups being optionally substituted with one to four substituents independently selected from halo, C1-C4alkyl, OC1-C4alkyl, and C(O)C1-C4alkyl;
R15 is selected from H and C1-C6alkyl;
each R16 is independently selected from H, C1-C6alkyl, C3-C7cycloalkyl, C3-C10heterocycloalkyl, C6-C10aryl, and C5-C10heteroaryl, the latter four groups being optionally substituted with one to four substituents independently selected from halo, C1-C4alkyl, OC1-C4alkyl, and C(O)C1-C4alkyl;
each R17 is independently selected from H and C1-C6alkyl;
each R18 is independently selected from H and C1-C6alkyl;
R19 is selected from H and C1-C6alkyl;
each R20 is independently selected from H and C1-C6alkyl; and
available hydrogen atoms of R2, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R16, R17, R18, R19, and R20 are optionally replaced with a halogen atom and/or available hydrogen atoms of R1, R2, R3, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R16, R17, R18, R19, and R20 are optionally replaced with deuterium;
provided when R1 is H, R2, R3, R4, R5, R7, R8, R9, and R10 are H or D, and R6 is H, C1-4alkyl, or C1-4deuteroalkyl, then R11 and R12 are not H, C1-4alkyl, or C1-4deuteroalkyl; and
provided when R1, R2, R3, R4, R5, R7, R8, R9, and R10 are H or D, and R6 is CH3 or CHF2, then R11 and R12 are not CH3 or CD3.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R6 is selected from C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkyleneZR14, C2-C6alkenyleneZR14, C2-C6alkynyleneZR14, C3-C7cycloalkyl, C3-C10heterocycloalkyl, and C1-C4alkyleneC3-C7cycloalkyl, the latter three groups being optionally substituted with one to four substituents independently selected from halo, C1-C6alkyl, OR15, and C(O)R15, and wherein available hydrogen atoms of R2, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R16, R17, R18, R19, and R20 are optionally replaced with a fluorine atom and/or a chlorine atom and/or available hydrogen atoms of R1, R2, R3, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R16, R17, R18, R19, and R20 are optionally replaced with deuterium.

### Claim 3 (depends on 1)

The compound of claim 1, wherein:
R7 is selected from H, D, F, Cl, Br, C1-C4alkyl, C1-C4fluoroalkyl, C1-C4deuteroalkyl, and C1-C4deuterofluoroalkyl;
R8 is selected from H, D, F, Cl, Br, C1-C4alkyl, C1-C4fluoroalkyl, C1-C4deuteroalkyl, and C1-C4deuterofluoroalkyl;
R9 is selected from H, D, F, Cl, and Br; and
R10 is selected from H, D, F, Cl, and Br.

### Claim 4 (depends on 1)

The compound of claim 1, wherein:
R7 is selected from H, F, and D;
R8 is selected from H, F, and D;
R9 is selected from H, F, and D; and
R10 is selected from H, F, and D.

### Claim 5 (depends on 1)

The compound of claim 1, wherein:
R11 is selected from H, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkyleneZ′R16, C2-C6alkenyleneZ′R16, C2-C6alkynyleneZ′R16, C3-C7cycloalkyl, C3-C10heterocycloalkyl, C6-C10aryl, C5-C10heteroaryl, C1-C4alkyleneC3-C7cycloalkyl, C1-C4alkyleneC3-C10heterocycloalkyl, C1-C4alkyleneC6-C10aryl, and C1-C4alkyleneC5-C10heteroaryl, the latter eight groups being optionally substituted with one to four substituents independently selected from halo, C1-C6alkyl, OR17, and C(O)R17, and wherein available hydrogen atoms of R2, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R16, R17, R18, R19, and R20 are optionally replaced with a fluorine atom and/or a chlorine atom and/or available hydrogen atoms of R2, R3, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R16, R17, R18, R19, and R20 are optionally replaced with deuterium; and
R12 is selected from C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkyleneZ′R16, C2-C6alkenyleneZ′R16, C2-C6alkynyleneZ′R16, C3-C7cycloalkyl, C3-C10heterocycloalkyl, C6-C10aryl, C5-C10heteroaryl, C1-C4alkyleneC3-C7cycloalkyl, C1-C4alkyleneC3-C10heterocycloalkyl, C1-C4alkyleneC6-C10aryl, and C1-C4alkyleneC5-C10heteroaryl, the latter eight groups being optionally substituted with one to four substituents independently selected from halo, C1-C6alkyl, OR17, and C(O)R17, and wherein available hydrogen atoms of R2, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R16, R17, R18, R19, and R20 are optionally replaced with a fluorine atom and/or a chlorine atom and/or available hydrogen atoms of R1, R2, R3, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R16, R17, R18, R19, and R20 are optionally replaced with deuterium.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R11, R12, or each of R11 and R12 is independently selected from C1-C6alkyleneZ′R16, C1-C6fluoroalkyleneZ′R16, C1-C6deuteroalkyleneZ′R16, and C1-C6deuterofluoroalkyleneZ′R16.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R11 and R12 are taken together with the nitrogen atom therebetween to form a monocyclic 3- to 7-membered heterocyclic ring optionally comprising 1 to 3 additional ring heteromoieties selected from O, S, S(O), SO2, N, and NR18 and/or optionally comprising one or two C═O groups, wherein said monocyclic 3- to 7-membered heterocyclic ring is further optionally substituted with one to four substituents independently selected from halo, C1-C6alkyl, OH, OC1-C6alkyl, C1-C6alkenyleneOH, and C1-C6alkyleneOC1-C6alkyl, wherein available hydrogen atoms of R2, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R16, R17, R18, R19, and R20 are optionally replaced with a halogen atom and/or available hydrogen atoms of R1, R2, R3, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R16, R17, R18, R19, and R20 are optionally replaced with deuterium.

### Claim 8 (depends on 1)

The compound of claim 1, wherein R11 and R12 are taken together with the nitrogen atom therebetween to form a monocyclic 3- to 7-membered heterocyclic ring, wherein said monocyclic 3- to 7-membered heterocyclic ring is further optionally substituted with one to four substituents independently selected from halo, C1-C6alkyl, OH, OC1-C6alkyl, C1-C6alkyleneOH, and C1-C6alkenyleneOC1-C6alkyl, and wherein available hydrogen atoms of R2, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R16, R17, R18, R19, and R20 are optionally replaced with a halogen atom and/or available hydrogen atoms of R1, R2, R3, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R16, R17, R18, R19, and R20 are optionally replaced with deuterium.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R11 and R12 are taken together with the nitrogen atom therebetween to form a monocyclic 3- to 7-membered heterocyclic ring including at least one substituent selected from OH, OC1-C4alkyl, OC1-C4deuteroalkyl, OC1-C4fluoroalkyl, OC1-C4deuterofluoroalkyl, C1-C4alkyleneOH, C1-C4fluoroalkyleneOH, C1-C4deuteroalkyleneOH, C1-C4deuterofluoroalkyleneOH, C1-C4alkyleneOC1-C4alkyl, C1-C4alkyleneOC1-C4fluoroalkyl, C1-C4alkyleneOC1-C4deuteroalkyl, C1-C4alkyleneOC1-C4deuterofluoroalkyl, C1-C4fluoroalkyleneOC1-C4alkyl, C1-C4deuteroalkyleneOC1-C4alkyl, C1-C4deuterofluoroalkyleneOC1-C4alkyl, C1-C4fluoroalkyleneOC1-C4fluoroalkyl, C1-C4fluoroalkyleneOC1-C4deuteroalkyl, C1-C4deuteroalkyleneOC1-C4fluoroalkyl, C1-C4deuteroalkyleneOC1-C4deuteroalkyl, C1-C4deuterofluoroalkyleneOC1-C4fluoroalkyl, C1-C4fluoroalkyleneOC1-C4deuterofluoroalkyl, and C1-C4deuterofluoroalkyleneOC1-C4deuterofluoroalkyl, and wherein available hydrogen atoms of R2, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R16, R17, R18, R19, and R20 are optionally replaced with a halogen atom and/or available hydrogen atoms of R1, R2, R3, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R16, R17, R18, R19, and R20 are optionally replaced with deuterium.

### Claim 10 (depends on 1)

The compound of claim 1, wherein R11 and R12 are taken together with the nitrogen atom therebetween to form a monocyclic 3- to 7-membered heterocyclic ring selected from aziridinyl, azetidinyl, diazetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, morpholinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl dioxide, azepanyl, diazepanyl, and 2,5-pyrrolidinedionyl, each of which is optionally substituted with one to four substituents independently selected from halo, C1-C6alkyl, OfH, OC1-C6alkyl, C1-C6alkyleneOH, and C1-C6alkyleneOC1-C6alkyl, and wherein available hydrogen atoms of R2, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R16, R17, R18, R19, and R20 are optionally replaced with a halogen atom and/or available hydrogen atoms of R1, R2, R3, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R16, R17, R18, R19, and R20 are optionally replaced with deuterium.

### Claim 11 (depends on 1)

The compound of claim 1, wherein R6 is selected from H, C1-C10alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkenyleneZR14, C2-C6alkenyleneZR14, C2-C6alkynyleneZR14, C3-C7cycloalkyl, C3-C10heterocycloalkyl, C1-C6alkenyleneC3-C7cycloalkyl, and C1-C6alkenyleneC3-C10heterocycloalkyl, the latter four groups being optionally substituted with one to four substituents independently selected from halo, C1-C6alkyl, OR15, and C(O)R15.

### Claim 12 (depends on 1)

The compound of claim 1, wherein R6 is selected from

### Claim 13 (depends on 1)

The compound of claim 1, wherein R6 is selected from

### Claim 14 (depends on 1)

The compound of claim 1, wherein:
R11 is selected from
and
R12 is selected from

### Claim 15 (depends on 1)

The compound of claim 1, wherein R11 and R12 are taken together with the nitrogen atom therebetween to form a monocyclic 3- to 7-membered heterocyclic ring selected from

### Claim 16 (depends on 1)

The compound of claim 1, wherein:
R2 is H;
R4 is H;
R5 is H;
R6 is selected from C1-C6alkyl, C3-C7-cycloalkyl, C3-C10heterocycloalkyl, C1-C6alkyleneZR14, and C1-C6alkenyleneC3-C10heterocycloalkyl;
R7 is selected from H and D;
R8 is selected from H and D;
R9 is selected from H and D;
R10 is selected from H and D;
R11 is selected from H, D, C1-C6alkyl and C1-C6alkyleneZR16;
R12 is selected from CH3, C1-C4alkyleneOCH3, C1-C4alkyleneOCHF2, C1-C4alkyleneOCH2F,
and C1-C6alkyleneC6-C10heteroaryl, the last group is optionally substituted with one to four substituents independently selected from OR17;
R14 is selected from C1-C6alkyl;
Z is selected from O, NR19C(O), and NR18C(O)O;
Z′ is O;
R16 is C1-C6alkyl;
R17 is C1-C6alkyl;
R18 is H; and
R19 is H.

### Claim 17 (depends on 1)

The compound of claim 1, wherein:
R2 is H;
R4 is H;
R5 is H;
R6 is selected from C1-C6alkyl, C3-C7cycloalkyl, C3-C10heterocycloalkyl, C1-C6alkenyleneZR14, and C1-C6alkenyleneC3-C10heterocycloalkyl;
R7 is selected from H and D;
R8 is selected from H and D;
R9 is selected from H and D;
R10 is selected from H and D;
R11 and R12 are taken together with the nitrogen atom therebetween to form a monocyclic 3- to 7-membered heterocyclic ring, wherein said monocyclic 3- to 7-membered heterocyclic ring is further optionally substituted with one to four substituents independently selected from OC1-C6alkyl;
R14 is selected from C1-C6alkyl;
Z is selected from NR19C(O) and NR18C(O)O;
R18 is H; and
R19 is H.

### Claim 18 (depends on 1)

The compound of claim 1, wherein:
R2 is H;
R4 is H;
R5 is H;
R6 is selected from CH3, CD3, CH(CH3)2, CH2CH2OCHF2, CH2CH2CH2OCHF2,
R7 is selected from H and D;
R8 is selected from H and D;
R9 is selected from H and D;
R10 is selected from H and D;
R11 is selected from H, D, CH3, CD3,
and CH2CH2OCHF2;
R12 is selected from CH3, CH2CH2OCHF2, CD2CH2OCHF2, CH2CD2OCHF2, CD2CD2OCHF2, CD2CH2OCDF2, CH2CD2OCDF2, CD2CD2OCDF2, and

### Claim 19 (depends on 1)

The compound of claim 1, wherein:
R2 is H;
R4 is H;
R5 is H;
R6 is selected from CH3, CD3, CHF2, CF3, CFD2, CDF2, CH(CH3)2,
R7 is selected from H and D;
R8 is selected from H and D;
R9 is selected from H and D;
R10 is selected from H and D;
R11 and R12 are taken together with the nitrogen atom therebetween to form a monocyclic 3- to 7-membered heterocyclic ring selected from

### Claim 20 (depends on 1)

The compound of claim 1, wherein:
R2 is H;
R4 is H;
R5 is H;
R6 is selected from CH3, CD3, CHF2, CF3, CFD2, CDF2, CH(CH3)2,
R7 is selected from H and D;
R8 is selected from H and D;
R9 is selected from H and D;
R10 is selected from H and D; and
R11 and R12 are taken together with the nitrogen atom therebetween to form a monocyclic 3- to 7-membered heterocyclic ring selected from

### Claim 21 (depends on 1)

The compound of claim 1, wherein the compound of Formula (I) is selected from the table below:
Com-
pound
Structure
(S) I-66
(R) I-66
(S) I-67
(R) I-67
(S) I-68
(R) I-68
(R) I-69
(S) I-69
I-70
I-71
I-72
I-73
(S) I-74
(R) I-74
(R) I-75
(S) I-75
(R, S) I-76
(S, S) I-76
(S) I-77
(S) I-78
(S) I-79
(S, S) I-80
(R, S) I-80
(S) I-81
(S) I-82
(S) I-83
(S) I-84
(S) I-85
(S) I-86
(S) I-87
Cis (S) I-88
(S) I-89
(S) I-90
(S) I-91
(S) I-92
I-93
(R) I-94
(S) I-95
I-96
(R) I-97
(S) I-97
I-98
I-99
I-100
(S) I-101
(R) I-101
I-102
I-103
I-104
I-105
I-106
I-107
I-108
Cis I-109
I-110
I-111
I-112
I-113
I-128
and
I-129
or a pharmaceutically acceptable salt, solvate, and/or prodrug thereof.

### Claim 22 (depends on 1)

The compound of claim 1, wherein the compound of Formula (I) is selected from the table below:
Compound
Structure
I-131
I-132
I-133
I-134
I-136
I-137
I-138
I-139
I-140
I-141
I-142
I-143
I-144
I-145
I-146
I-147
I-148
I-149
I-150
I-151
I-152
I-153
and
I-154
or a pharmaceutically acceptable salt, solvate, and/or prodrug thereof.

### Claim 23 (depends on 1)

The compound of claim 1, wherein the compound of Formula (I) is selected from the table below:
Compound
Structure
(S) I-157
(R) I-157
(S) I-158
(R) I-158
(S) I-159
(R) I-159
I-160
(R) I-161
(S) I-162
(R) I-163
(R) I-164
(S) I-164
(S) I-165
((S) I-166
I-167
I-168
I-169
I-170
I-171
I-172
I-173
I-174
I-175
I-176
I-177
I-178
I-179
I-180
I-181
I-182
(S) I-190
(R) I-190
I-191
(S) I-192
(S) I-193
(S) I-194
I-195
I-196
I-197
I-198
I-199
(R) I-200
(R) I-201
(R) I-202
(R) I-203
(R) I-204
and
(R) I-205
II-80
II-81
II-82
II-83
II-84
II-85
or a pharmaceutically acceptable salt, solvate, and/or prodrug thereof.

### Claim 24 (depends on 1)

A pharmaceutical composition comprising one or more compounds of claim 1 and a pharmaceutically acceptable carrier.

### Claim 25 (depends on 1)

A method of treating a mental illness, comprising administering a therapeutically effective amount of one or more compounds of claim 1 to a subject in need thereof, wherein the mental illness is selected from anxiety disorders, generalized anxiety disorder, social anxiety disorder, depression, cancer-related depression, major depressive disorder (MDD), treatment-resistant depression (TRD), postpartum depression (PPD), anxiety, alcohol addiction, drug addiction, opioid addiction, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and combinations thereof.

### Claim 26 (depends on 1)

A method of treating a central nervous system (CNS) disease, disorder, or condition and/or a neurological disease, disorder, or condition comprising administering a therapeutically effective amount of one or more compounds of claim 1 to a subject in need thereof.

### Claim 27 (depends on 26)

The method of claim 26, wherein the CNS disease, disorder, or condition and/or neurological disease, disorder, or condition is selected from Alzheimer's disease; presenile dementia; senile dementia; vascular dementia; Lewy body dementia; cognitive impairment, Parkinson's disease and Parkinsonian related disorders; epilepsy; CNS trauma; CNS infections; CNS inflammation; stroke; multiple sclerosis; Huntington's disease; mitochondrial disorders; Fragile X syndrome; Angelman syndrome; hereditary ataxias; neuro-otological and eye movement disorders; neurodegenerative diseases of the retina amyotrophic lateral sclerosis; tardive dyskinesias; hyperkinetic disorders; attention deficit hyperactivity disorder and attention deficit disorders; restless leg syndrome; Tourette's syndrome; schizophrenia; autism spectrum disorders; tuberous sclerosis; Rett syndrome; cerebral palsy; disorders of the reward system binge eating disorder (“BED”); pica; rumination disorder; avoidant/restrictive food intake disorder; trichotillomania; dermotillomania; nail biting; migraine; fibromyalgia; peripheral neuropathy of any etiology; reduction in convergent thinking; increase in spontaneous divergent thinking and goal-oriented divergent thinking; and combinations thereof.

### Claim 28

A compound of Formula (I)
or a pharmaceutically acceptable salt, solvate, and/or prodrug thereof,
wherein:
X is O;
R1 is H;
R2 is selected from H, halo, and C1-C6alkyl;
R3 is H;
R4 is selected from H, CN, halo, C1-C6alkyl, C2-C6alkenyl, and C2-C6alkynyl;
R5 is selected from H, CN, halo, C1-C6alkyl, C2-C6alkenyl, and C2-C6alkynyl;
R6 is selected from H, C1-C10alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkenyleneZR14, C2-C6alkenyleneZR14, C2-C6alkynyleneZR14, C3-C7cycloalkyl, C3-C10heterocycloalkyl, C1-C6alkenyleneC3-C7cycloalkyl, C1-C6alkenyleneC3-C10heterocycloalkyl, and C1-C6alkenyleneC5-C10heteroaryl, the latter five groups being optionally substituted with one to four substituents independently selected from halo, C1-C6alkyl, OR15, and C(O)R15;
R7 is selected from H, halo, and C1-C6alkyl;
R8 is selected from H, halo, and C1-C6alkyl;
R9 is selected from H and halo;
R10 is selected from H and halo;
R11 is selected from H, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkyleneZ′R16, C2-C6alkenyleneZ′R16, C2-C6alkynyleneZ′R16, C3-C7cycloalkyl, C3-C10heterocycloalkyl, C6-C10aryl, C5-C10heteroaryl, C1-C6alkyleneC3-C7cycloalkyl, C1-C6alkenyleneC3-C10heterocycloalkyl, C1-C6alkenyleneC6-C10aryl, and C1-C6alkyleneC5-C10heteroaryl, the latter eight groups being optionally substituted with one to four substituents independently selected from halo, C1-C6alkyl, OR17, and C(O)R17;
R12 is selected from C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkyleneZ′R16, C2-C6alkenyleneZ′R16, C2-C6alkynyleneZ′R16, C3-C7cycloalkyl, C3-C10heterocycloalkyl, C6-C10aryl, C5-C10heteroaryl, C1-C6alkyleneC3-C7cycloalkyl, C1-C6alkyleneC3-C10heterocycloalkyl, C1-C6alkenyleneC6-C10aryl, and C1-C6alkenyleneC5-C10heteroaryl, the latter eight groups being optionally substituted with one to four substituents independently selected from halo, C1-C6alkyl, OR17, and C(O)R17; or
R11 and R12 are taken together with the nitrogen atom therebetween to form a monocyclic 3- to 7-membered heterocyclic ring optionally comprising 1 to 3 additional ring heteromoieties selected from O, S, S(O), SO2, N, and NR18 and/or optionally comprising one or two C═O groups, wherein said monocyclic 3- to 7-membered heterocyclic ring is further optionally substituted with one to four substituents independently selected from halo, C1-C6alkyl, OH, OC1-C6alkyl, C1-C6alkyleneOH, and C1-C6alkenyleneOC1-C6alkyl;
Z is selected from O, C(O), NR19C(O), NR18C(O)O, C(O)NR19, OC(O)NR19, and NR19;
each Z′ is independently selected from O, C(O), NR20C(O), NR20C(O)O, C(O)NR20, OC(O)NR20, and NR20;
R14 is selected from H, C3-C7cycloalkyl, C3-C10heterocycloalkyl, C6-C10aryl, and C5-C10heteroaryl, the latter four groups being optionally substituted with one to four substituents independently selected from halo, C1-C4alkyl, OC1-C4alkyl, and C(O)C1-C4alkyl;
R15 is selected from H and C1-C6alkyl;
each R16 is independently selected from H, C1-C6alkyl, C3-C7cycloalkyl, C3-C10heterocycloalkyl, C6-C10aryl, and C5-C10heteroaryl, the latter four groups being optionally substituted with one to four substituents independently selected from halo, C1-C4alkyl, OC1-C4alkyl, and C(O)C1-C4alkyl;
each R17 is independently selected from H and C1-C6alkyl;
each R18 is independently selected from H and C1-C6alkyl;
R19 is H;
each R20 is independently selected from H and C1-C6alkyl; and
available hydrogen atoms of R2, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R16, R17, R18 R19, and R20 are optionally replaced with a halogen atom and/or available hydrogen atoms of R1, R2, R3, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R16, R17, R18, R19, and R20 are optionally replaced with deuterium;
provided when R1 is H, R2, R3, R4, R5, R7, R8, R9, and R10 are H or D, and R6 is H, C1-4alkyl, or C1-4deuteroalkyl, then R11 and R12 are not H, C1-4alkyl, or C1-4deuteroalkyl; and
provided when R1, R2, R3, R4, R5, R7, R8, R9, and R10 are H or D, and R6 is CH3 or CHF2, then R11 and R12 are not CH3 or CD3.

### Claim 29

A compound of Formula (I)
or a pharmaceutically acceptable salt, solvate, and/or prodrug thereof, wherein:
X is O;
R1 is H;
R2 is selected from H, halo, and C1-C6alkyl;
R3 is H;
R4 is selected from H, CN, halo, C1-C6alkyl, C2-C6alkenyl, and C2-C6alkynyl;
R5 is selected from H, CN, halo, C1-C6alkyl, C2-C6alkenyl, and C2-C6alkynyl;
R6 is selected from H, C1-C10alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkyleneZR14, C2-C6alkenyleneZR14, C2-C6alkynyleneZR14, C3-C7cycloalkyl, C3-C10heterocycloalkyl, C1-C6alkyleneC3-C7cycloalkyl, C1-C6alkyleneC3-C10heterocycloalkyl, and C1-C6alkyleneC5-C10heteroaryl, the latter five groups being optionally substituted with one to four substituents independently selected from halo, C1-C6alkyl, OR15, and C(O)R15;
R7 is selected from H, halo, and C1-C6alkyl;
R8 is selected from H, halo, and C1-C6alkyl;
R9 is selected from H and halo;
R10 is selected from H and halo;
R11 and R12 are taken together with the nitrogen atom therebetween to form a monocyclic 3- to 7-membered heterocyclic ring optionally comprising 1 to 3 additional ring heteromoieties selected from O, S, S(O), SO2, N, and NR18 and/or optionally comprising one or two C═O groups, wherein said monocyclic 3- to 7-membered heterocyclic ring is further optionally substituted with one to four substituents independently selected from halo, C1-C6alkyl, OH, OC1-C6alkyl, C1-C6alkyleneOH, and C1-C6alkyleneOC1-C6alkyl;
Z is selected from O, C(O), NR10C(O), NR18C(O)O, C(O)NR19, OC(O)NR19, and NR19;
each Z′ is independently selected from O, C(O), NR20C(O), NR20C(O)O, C(O)NR20, OC(O)NR20, and NR20;
R14 is selected from H, C1-C6alkyl, C3-C7cycloalkyl, C3-C10heterocycloalkyl, C6-C10aryl, and C5-C10heteroaryl, the latter four groups being optionally substituted with one to four substituents independently selected from halo, C1-C4alkyl, OC1-C4alkyl, and C(O)C1-C4alkyl;
R15 is selected from H and C1-C6alkyl;
each R18 is independently selected from H and C1-C6alkyl;
R19 is selected from H and C1-C6alkyl;
each R20 is independently selected from H and C1-C6alkyl; and
available hydrogen atoms of R2, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R18, R19, and R20 are optionally replaced with a halogen atom and/or available hydrogen atoms of R1, R2, R3, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R18, R19, and R20 are optionally replaced with deuterium;
provided when R1 is H, R2, R3, R4, R5, R7, R8, R9, and R10 are H or D, and R6 is H, C1-4alkyl, or C1-4deuteroalkyl, then R11 and R12 are not H, C1-4alkyl, or C1-4deuteroalkyl; and
provided when R1, R2, R3, R4, R5, R7, R8, R9, and R10 are H or D, and R6 is CH3 or CHF2, then R11 and R12 are not CH3 or CD3.

### Claim 30

A compound of Formula (I)
or a pharmaceutically acceptable salt, solvate, and/or prodrug thereof,
wherein:
X is O;
R1 is H;
R2 is selected from H, halo, and C1-C6alkyl;
R3 is H;
R4 is selected from H, CN, halo, C1-C6alkyl, C2-C6alkenyl, and C2-C6alkynyl;
R5 is selected from H, CN, halo, C1-C6alkyl, C2-C6alkenyl, and C2-C6alkynyl;
R6 is selected from H, C1-C10alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkyleneZR14, C2-C6alkenyleneZR14, C2-C6alkynyleneZR14, C3-C7cycloalkyl, C3-C10heterocycloalkyl, C1-C6alkyleneC3-C7cycloalkyl, C1-C6alkyleneC3-C10heterocycloalkyl, and C1-C6alkyleneC5-C10heteroaryl, the latter five groups being optionally substituted with one to four substituents independently selected from halo, C1-C6alkyl, OR15, and C(O)R15;
R7 is selected from H, halo, and C1-C6alkyl;
R8 is selected from H, halo, and C1-C6alkyl;
R9 is selected from H and halo;
R10 is selected from H and halo;
R11 is selected from H, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkyleneZ′R16, C2-C6alkenyleneZ′R16, C2-C6alkynyleneZ′R16, C3-C7cycloalkyl, C3-C10heterocycloalkyl, C6-C10aryl, C5-C10heteroaryl, C1-C6alkyleneC3-C7cycloalkyl, C1-C6alkyleneC3-C10heterocycloalkyl, C1-C6alkyleneC6-C10aryl, and C1-C6alkenyleneC5-C10heteroaryl, the latter eight groups being optionally substituted with one to four substituents independently selected from halo, C1-C6alkyl, OR17, and C(O)R17;
R12 is selected from C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkyleneZ′R16, C2-C6alkenyleneZ′R16, C2-C6alkynyleneZ′R16, C3-C7cycloalkyl, C3-C10heterocycloalkyl, C6-C10aryl, C5-C10heteroaryl, C1-C6alkenyleneC3-C7cycloalkyl, C1-C6alkyleneC3-C10heterocycloalkyl, C1-C6alkyleneC6-C10aryl, and C1-C6alkenyleneC5-C10heteroaryl, the latter eight groups being optionally substituted with one to four substituents independently selected from halo, C1-C6alkyl, OR17, and C(O)R17; or
R11 and R12 are taken together with the nitrogen atom therebetween to form a bicyclic 7- to 10-membered heterocyclic ring optionally comprising 1 to 3 additional ring heteromoieties selected from O, S, S(O), SO2, N, and NR18 and/or optionally comprising only one C═O group, wherein said bicyclic 7- to 10-membered heterocyclic ring is further optionally substituted with one to four substituents independently selected from halo, C1-C6alkyl, OH, OC1-C6alkyl, C1-C6alkyleneOH, and C1-C6alkyleneOC1-C6alkyl;
Z is selected from O, C(O), NR19C(O), NR18C(O)O, OC(O)NR19, and NR19;
each Z′ is independently selected from O, C(O), NR20C(O), NR20C(O)O, C(O)NR20, OC(O)NR20, and NR20;
R14 is selected from H, C1-C6alkyl, C3-C7cycloalkyl, C3-C10heterocycloalkyl, C6-C10aryl, and C5-C10heteroaryl, the latter four groups being optionally substituted with one to four substituents independently selected from halo, C1-C4alkyl, OC1-C4alkyl, and C(O)C1-C4alkyl;
R15 is selected from H and C1-C6alkyl;
each R16 is independently selected from H, C1-C6alkyl, C3-C7cycloalkyl, C3-C10heterocycloalkyl, C6-C10aryl, and C5-C10heteroaryl, the latter four groups being optionally substituted with one to four substituents independently selected from halo, C1-C4alkyl, OC1-C4alkyl, and C(O)C1-C4alkyl;
each R17 is independently selected from H and C1-C6alkyl;
each R18 is independently selected from H and C1-C6alkyl;
R19 is selected from H and C1-C6alkyl;
each R20 is independently selected from H and C1-C6alkyl; and
available hydrogen atoms of R2, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R16, R17, R18 R19, and R20 are optionally replaced with a halogen atom and/or available hydrogen atoms of R1, R2, R3, R4, R5, R6, R7 R8, R9, R10, R11, R12, R14, R15, R16, R17, R18, R19, and R20 are optionally replaced with deuterium;
provided when R1 is H, R2, R3, R4, R5, R7, R8, R9, and R10 are H or D, and R6 is H, C1-4alkyl, or C1-4deuteroalkyl, then R11 and R12 are not H, C1-4alkyl, or C1-4deuteroalkyl; and
provided when R1, R2, R3, R4, R5, R7, R8, R9, and R10 are H or D, and R6 is CH3 or CHF2, then R11 and R12 are not CH3 or CD3.
